Antagonistic effects of bifidobacterium spp. in decrease of cytopathic effects of Verotoxin-producing Escherichia coli
Subject Areas : Medical Microbiology
Najmeh
Namdar
1
(Jahrom Branch, Young Researchers clube, Islamic Azad University, Jahrom, Iran)
Mohammad
Kargar
2
(Department of Microbiology, Jahrom Branch, Islamic Azad University, Jahrom, Iran)
Yahya
Tahamtan
3
(Department of Bacteriology, Razi Vaccine and Seum Research Institute, Shiraz, Iran)
Mohammad Hosein
Hoseini
4
(Department of Bacteriology, Razi Vaccine and Seum Research Institute, Shiraz, Iran)
Keywords: Probiotic, E.coli O157:H7, Shiga Toxin, bifidobacterium,
Abstract :
Background and Objectives: Most Enterohemorrhagic E. coli O157:H7 strains are able to adhere to Vero cell line tightly and produce shiga toxin. The aim of this study was to develop a probiotic in vitro model for protection against E. coli O157:H7. Materials and Methods: This study was performed experimentally on probiotic Bifidobacterium and shigatoxinogen E.coli O157:H7 in Vero cell line monolayers. The probiotic bacterium first was grown in MRS media and then was transferred into the vero cell line-containing wells. After incubation, the cells were first exposed to three different treatments (pure stx1, stx2, a mix of stx1and stx2) and then were treated with E. coli O157:H7 bacterial culture. After 24 h incubation at 37° C in CO2 incubator, the cell changes were observed by invert microscope. Results: The vero cell lines pre-treated with probiotic bacterium responded differently to the doses of used Shiga-toxin and E. coli O157:H7. When the cells were treated with only toxin or E. coli O157:H7, there was a intensive amounts of cell cytotoxicity. However, pre-treatment with prebiotic bacterium decrease significantly the toxicity caused by E. coli O157:H7. The survival rates of the Vero cells treated with probiotic ranged between 80% and 100% compared with controls. Conclusion: Based on the results of this study, the probiotic bacteria and the supernatant prepared from their culture decrease the cell toxicity effects of shiga-toxin and E. coli O157:H7. Therefore, the probiotic bacteria can be used as an alive vaccine in food industry in order to prevent and treatment of infections.
1. Ochoa TJ and Cleary TG. XVI Infectious disease- Escherichia coli. Chapter 83. 2005; 9: 921-924.
2. Wang L, Li Y, Mustaphai A. Rapid and simultaneous quantitation of Escherichia coli 0157:H7, Salmonella, and Shigella in ground beef by multiplex real-time PCR and immunomagnetic separation. J Food Prot. 2007; 70(6): 1366-1372.
3. Natara JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998; 11(1): 142-201.
4. Boyce T, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the Hemolytic- Uremic Syndrome. N Engl J Med. 1995; 333(6): 364-368.
5. Osek J. Development of a multiplex PCR approach for the identification of shiga-toxin producing Escherichia coli strains and their major virulence factor genes. J Appl Microbiol. 2003; 95(6): 1217-1225.
6. Obrig TG. Shiga toxin mode of action in E. coli O157:H7 disease. Front Biosci. 1997; 2: 635-642.
7. Mkcp S, Hart AL, Kamm MA, Stagg AJ, Kinght SC. Mechanism action of probiotics: Recent advances. Inflamm Bowel Dis. 2008; 21: 756-781.
8. Picard C, Fioramonti J, Francois A, Robinson T, Neat F, Matuchansky C. Bifidobacteria as agents-physiological effect and clinical benefits. Aliment Pharmacol Ther. 2005; 22(6): 495-512.
9. Kiaei E, Amir Mozafari N, Samiol Adab H, Jandaghi N, Ghaemi E. Antagonistic effect of lactic bacteria present in yoghurt against pathogenic bacteria. J Gorgan Uni Med Sci. 2006; 8(17): 33-28. [In Persian]
10. Shin IS, Nishikawa K, Maruyama H, Ishii S. Histidine-tagged shiga toxin B subunit binding assay: simple and specific determination of gb3 content in mammalian cells. Chem Pharm Bull. 2006; 54: 522-527.
11. Gagnon M, Kheadr EE, Blay GL, Fliss I. In vitro inhibition of Escherichia coli O157:H7 by Bifidobacterial strains of human orgin. Food Microbiol. 2004, 92: 69-78.
12. Trejo FM, Minnaard J, Perez FP, De Antoni GL. Inhibition of Closttridum difficle growth and adhesion by Bifidobacterium supernatants. Anearobe. 2006, 12(4): 186-193.
13. Namdar N, Tahamtan Y, Kargar M, Hoseini MH. Evaluation of antagonistic effect of probiotics Bifidobacteria spp. on E. coli O157:H7 in vitro. J Microb World. 2009, 2(3): 161-168. [In Persian]
14. Pamela HR, Davis KC, Garstka WR, Bhunia AK. Lactat dehydrogenase realase assay from vero cells to distinguish vero toxin producing Eschrichia coli from non vero toxin producing strains. J Microbiol Methods. 2000; 43(3): 171-178.
15. Takahashi M, Taguchi H, Yamaguchi H, Asaki T, Kamiya S. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O15: H7 infection in mice. FEMS Immun Med Microbiol. 2004; 41: 219-266.
16. Johnson–Henry KC, Donato KA, Shen-Tu G, Gordanpour, MandSherman P M. Lactobacillus rhamnosus strain GG prevents Enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun. 2008; 76(4): 1340-1348.
17. Konwalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977; 18: 775-779.
18. Sprirs JI, Stavric S, Konowalchuk J. Assay of Escherichia coli Heat -Labile Enterotoxin with Vero cells. Infect Immun. 1997; 16(2): 617-622.
19. Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PC, Goulet J. Probiotics reduce enterohemorrhag Escherichia coli O157: H7 and enter pathogenic E. coli O157: H6 induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and scytoskeletal rearrangements. Infect Immum. 2005; 73(8): 5183-5188.
20. Boyd B, Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nephron .1989; 51(2): 207-210.
21. Su C, Berent JL. Escherichia coli O157:H7 Infection in Humans. Ann Intern Med. 1995; 123(9): 698-707.
22. Johnson-Henry KC, Hagen KE, Gordanpour M, Tompkins TA, Sherman PM. Surface-Layer Protein extracts from Lactobacillus helvicus inhibit enterohaemorrhagic Escherichia coli O157: H7 adhesion to epithelial cells. Cell Microbiol. 2007; 9(2): 356-36.
